Friday 6 November 2026 Export KRYS’s income statement to Excel — free account

Krystal Biotech, Inc.

Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.

Revenue: +30.2%
EPS: −22.3%
Free cash flow: +137.8%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

301.33 1.08 +0.36%

Follow KRYS

Alert me

Market cap: $8.9B
P/E: 39.2×
Fwd P/E: 45.7×
Dividend yield: —
F-score: 7/9
Altman Z: 39.03
Beneish M: −2.27
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Krystal Biotech, Inc. (KRYS) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Krystal Biotech, Inc. (KRYS) trades at a P/B ratio of 6.2×. Over the past ten years it has ranged from 0.0× (September 2017) to 8.7× (June 2026); the current reading is higher than 88% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/KRYS/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Krystal Biotech, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/KRYS/metrics/pb-ratio">Krystal Biotech, Inc. (KRYS) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	5.9×	23.63%
FY2024	4.7×	8.61%
FY2023	4.4×	—

Period	P/B ratio	Change
Sep 2026	6.9×	(15.06%)
Jun 2026	8.1×	36.27%
Mar 2026	5.9×	1.27%
Dec 2025	5.9×	30.26%
9 more quarters	Free account

Against its own ten years

Low 0.0× High 8.7×

Ten-year median 4.0×

Current reading's percentile 88

Company	P/B ratio
CYTK Cytokinetics, Incorporated compare	n/m
IBRX ImmunityBio, Inc. compare	n/m
KRYS Krystal Biotech, Inc.	6.2×
SYRE Spyre Therapeutics, Inc. compare	9.5×
PTGX Protagonist Therapeutics, Inc. compare	10.6×
CAI Caris Life Sciences,�Inc. compare	12.7×
TGTX TG Therapeutics, Inc. compare	13.6×
TWST Twist Bioscience Corporation compare	17.1×
MDGL Madrigal Pharmaceuticals, Inc. compare	18.7×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Krystal Biotech, Inc. (KRYS) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on KRYS

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on KRYS

Stockrow Weekly